ADAGENE INC. SP.ADR (F:978) — Market Cap & Net Worth
Market Cap & Net Worth: ADAGENE INC. SP.ADR (978)
ADAGENE INC. SP.ADR (F:978) has a market capitalization of $237.92 Million (€203.50 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #15973 globally and #1533 in its home market, demonstrating a -2.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ADAGENE INC. SP.ADR's stock price €3.08 by its total outstanding shares 66072594 (66.07 Million). Also see 978 current and non-current assets for a full breakdown of the balance sheet.
ADAGENE INC. SP.ADR Market Cap History: 2021 to 2026
ADAGENE INC. SP.ADR's market capitalization history from 2021 to 2026. Data shows change from $834.25 Million to $224.01 Million (-30.38% CAGR). Also see 978 cash generation efficiency for how efficiently the company converts equity into cash flow.
ADAGENE INC. SP.ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ADAGENE INC. SP.ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 978 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.80x
ADAGENE INC. SP.ADR's market cap is 14.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $834.25 Million | $10.18 Million | -$73.18 Million | 81.99x | N/A |
| 2022 | $83.43 Million | $9.29 Million | -$79.97 Million | 8.98x | N/A |
| 2023 | $115.10 Million | $18.11 Million | -$18.95 Million | 6.35x | N/A |
| 2024 | $139.81 Million | $103.20K | -$33.42 Million | 1354.74x | N/A |
| 2025 | $113.55 Million | $7.67 Million | -$17.61 Million | 14.80x | N/A |
Competitor Companies of 978 by Market Capitalization
Companies near ADAGENE INC. SP.ADR in the global market cap rankings as of September 20, 2026. Review 978 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ADAGENE INC. SP.ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
ADAGENE INC. SP.ADR Historical Marketcap From 2021 to 2026
Between 2021 and today, ADAGENE INC. SP.ADR's market cap moved from $834.25 Million to $ 224.01 Million, with a yearly change of -30.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €224.01 Million | +97.28% |
| 2025 | €113.55 Million | -18.78% |
| 2024 | €139.81 Million | +21.48% |
| 2023 | €115.10 Million | +37.96% |
| 2022 | €83.43 Million | -90.00% |
| 2021 | €834.25 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ADAGENE INC. SP.ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $237.92 Million USD |
| MoneyControl | $237.92 Million USD |
| MarketWatch | $237.92 Million USD |
| marketcap.company | $237.92 Million USD |
| Reuters | $237.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more